DNA methylation and human diseases: An overview

DNA and RNA Modification Enzymes: Structure, Mechanism, Function and Evolution

Volumn , Issue , 2009, Pages 103-116

  Schulz, Wolfgang A ^a   Dokun, Olusola Y ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85050922469     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (82)

1. Viré E, Brenner C, Deplus R et al. The polycomb group protein EZH2 directly controls DNA méthylation. Nature 2006; 439:871-874.
2. Muegge K. Lsh, a guardian of Heterochromatin at repeat elements. Biochem Cell Biol 2005; 83:548-54.
3. Vaissière X Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA méthylation in gene silencing. Mutât Res 2008; 659:40-48.
4. Kangaspeska S, Stride B, Métivicr R et al. Transient cyclical méthylation of promoter DNA. Nature 2008; 452:112-115.
5. Rcik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007; 447:425-432.
6. La Salle S, Oakes CC, Neaga OR et al. Loss of spermatogonia and wide-spread DNA méthylation defects in newborn male mice deficient in DNMT3L. BMC Dev Biol 2007; 7:104.
7. Mertineit C. Yoder JA, Taketo T et al Sex-specific exons control DNA methyltransferase in mammalian germ cells. Development 1998; 125:889-897.
8. Heard E, Disteche CM. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev 2006; 20:1848-1867.
9. Ogawa Y, Sun BK, Lee JT. Intersection of the RNA interference and X-inactivation pathways. Science2008; 320:1336-1341.
10. Goll MG, Bestor TH. Eukaryotic cytosine mcthyltransferases. Annu Rev Biochem 2005; 74:481-514.
11. Schulz WA, Steinhoff C, Florl AR. Méthylation of endogenous human retroelements in health and disease. Curr Topics Microbiol Immunol 2006; 310:211-250.
12. Steinhoff C, Schulz WA. Transcriptional regulation of the human LINE-1 retrotransposon L1.2B. Mol Genet Genomics 2003; 270:394-402.
13. Jelinic P, Shaw P. Loss of imprinting and cancer. J Pathol 2007; 211:261-268.
14. Miranda TB, Jones PA. DNA méthylation: the nuts and bolts of repression. J Cell Physiol 2007; 213:384-390.
15. Weber M, Hellmann I, Stadler MB et al. Distribution, silencing potential and evolutionary impact of promoter DNA méthylation in the human genome. Nat Genet 2007; 39442-39453.
16. Farthing CR, Fiez G, Ng RK et al Global mapping of DNA méthylation in mouse promoters reveals epigenetic reprogramming of pluripotency genes. PLoS Genet 2008; 4:e1000116.
17. Mohn F, Weber M, Rebhan M et al Lineage-specific polycomb targets and de novo DNA méthylation define restriction and potential of neuronal progenitors. Mol Cell 2008; 30:755-66.
18. Dokun OY, Florl AR, Seifert HH et al. Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA méthylation in bladder cancer. Int J Cancer 2008; 123:2798-2807.
19. Ehrlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol 2003; 109:17-28.
20. Robertson KD. DNA méthylation and human disease. Nat Rev Genet 2005; 6:597-610.
21. Jin B, Tao Q, Peng J et al DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogcncsis and immune function. Hum Mol Genet 2008; 17:690-709.
22. Scarano MI, Strazzullo M, Matarazzo MR et al. DNA méthylation 40 years later: its role in human health and disease. J Cell Physiol 2005: 204:21-35.
23. Garrick D, Sharpe JA, Arkell R et al Loss of atrx affects trophoblast development and the pattern of X-inactivarion in cxtraembryonic tissues. PLoS Genet 2006: 2:e58.
24. Tang P, Park DJ, Marshall Graves JA et al ATRX and sex differentiation. Trends Endocrinol Metab 2004; 15:339-344.
25. Bienvenu T, Chelly J. Molecular genetics of Rett syndrome: when DNA méthylation goes unrecognized. Nat Rev Genet 2006; 7:415-426.
26. Chang Q, Khare G, Dani V et al The disease progression of mecp2 Mutant mice is affected by the level of BDNF expression. Neuron 2006; 49:341-8.
27. Lalande M, Calciano MA. Molecular epigenctics of Angelman syndrome. Cell Mol Life Sci 2007; 64:947-60.
28. Horsthemke B, Wagstaff J. Mechanisms of imprinting of the Prader-Willi/Angelman region. Am J Med Genet 2008; 146A:2041-2052.
29. Mackay DJ, Hahnemann JM, Boonen SE et al. Epimutation of the TNDM locus and the Beckwith-Wiedemann syndrome centromceric locus in individuals with transient neonatal diabetes mellitus. Hum Genet 2006; 119:179-184.
30. Peters J, Williamson CM. Control of imprinting at the gnas cluster. Adv Exp Med Biol 2008; 626:16-26.
31. Jin P, Warren ST. Understanding the molecular basis of fragile X syndrome. Hum Mol Genet 2000; 9:901-908.
32. van der Maarel SM, Frants RR. The D4Z4 repeat-mediated pathogenesis of facioscapulohumeral muscular dystrophy. Am J Hum Genet 2005; 76:375-386.
33. Tsumagari K, Qi L, Jackson K et al Epigenctics of a tandem DNA repeat: chromatin DNasel sensitivity and opposite méthylation changes in cancers. Nucleic Acids Res 2008; 36:2196-2207.
34. Polansky JK, Kretschmer K, Freyer J et al DNA méthylation controls Foxp3 gene expression. Eur J Immunol 2008; 38:1654-63.
35. Landolfi MM, Scollay R, Pames JR. Specific déméthylation of the CD4 gene during CD4 T-lymphocyte differentiation. Mol Immunol 1997; 34:53-61.
36. Wilson CB, Makar KW, Shnyreva M et al. DNA méthylation and the expanding epigenerics of T-cell lineage commitment. Semin Immunol 2005; 17:105-119.
37. Reiner SL. Epigenetic control in the immune response. Hum Mol Genet 2005; 14:41-46.
38. Corcoran AE. Immunoglobulin locus silencing and allelic exclusion. Semin Immunol 2005; 17:141-154.
39. Santourlidis S, Graffinann N, Christ J et al. Lineage-specific transition of histone signatures in the killer cell Fg-like receptor locus from hematopoietic progenitor to NK cells. J Immunol 2008; 180:418-25.
40. McStay B, Grummt I. The epigenctics of rRNA genes: from molecular to chromosome biology. Annu Rev Cell Dev Biol 2008; 24:131-157.
41. Strickland FM, Richardson BC. Epigenctics in human autoimmunity. Epigenctics in autoimmunity—DNA méthylation in systemic lupus erythematosus and beyond. Autoimmunity 2008; 41:278-286.
42. Lee BH, Yegnasubramanian S, Lin X et al Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005; 280:40749-40756.
43. Sinchez-Pemaute O, Ospelt C, Neidhart M et al Epigenetic clues to rheumatoid arthritis. J Autoimmun2008; 30:12-20.
44. Perl A, Nagy G, Koncz A et al Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity 2008; 41:287-297.
45. Gilliet M, Lande R. Antimicrobial peptides and sclf-DNA in autoimmune skin inflammation. Curr Opin Immunol 2008; 20:401-407.
46. Kariko K, Wcissrnali D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 2007; 10:523-532.
47. Herrmann W. Significance of hypcrhomocysteincmia. Clin Lab 2006; 52:367-374.
48. Girelli D, Friso S, Trabetti E et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1999; 93:1118-1120.
49. Ulrcy CL, Liu L, Andrews LG et al The impact of metabolism on DNA méthylation. Hum Mol Genet2005; 14:R139-147.
50. Wilson AS, Power BE, Molloy PL. DNA hypomcthylation and human diseases. Biochim Biophys Acta2007; 1775:138-162.
51. James SJ, Mclnyk S, Pogribna M et al Elevation in S-adcnosylhomocystcine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002; 132:2361S-2366S.
52. Choi SW, Friso S. Interactions between folate and aging for carcinogenesis. Clin Chcm Lab Med 2005; 43:1151-1157.
53. Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005; 19:59-65.
54. Laird PW. Cancer epigenetics. Hum Mol Genet 2005: 14:R65-76.
55. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007; 16:R50-59.
56. Jones PA, Baylin SB. The epigcnomics of cancer. Cell 2007; 128:683-692.
57. Stresemann C, Lyko F. Modes of action of the DNA methyltransforase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123:8-13.
58. Strunnikova M, Schagdarsurengin U, Kehlen A et al. Chromatin inactivation precedes de novo DNA méthylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 2005; 25:3923-3933.
59. Park IK, Qian D, Kiel M et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423:302-305.
60. Ohm JE, McGarvey KM, Yu X et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hyperméthylation and heritable silencing. Nat Genet 2007; 39:237-242.
61. Schlesinger Y, Straussman R, Keshet I et al. Polycomb-mediatcd méthylation on Lys27 of histone H3 premarks genes for de novo méthylation in cancer. Nat Genet 2007; 39:232-236.
62. Hoffinann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 2005; 83:296-321.
63. Rodriguez J, Vives L, Jordà M et al. Genome-wide tracking of unmcthylated DNA Alu repeats in normal and cancer cells. Nucleic Acids Res 2008; 36:770-784.
64. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4:988-993.
65. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-130.
66. Florl AR, Steinhoff C, Midler M et al. Coordinate hyperméthylation at specific sites in prostate carcinoma precedes LINE-1 hypomethylation. Brit J Cancer 2004; 91:985-994.
67. Howard G, Eiges R, Gaudet F et al Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2008; 27:404-408.
68. Futscher BW, Oshiro MM, Wozniak RJ et al Role for DNA méthylation in the control of cell type specific maspin expression. Nat Genet 2002; 31:175-179.
69. Boyer LA, Lee TI, Cole MF et al Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122:947-956.
70. Li JY, Pu MT, Hirasawa R et al Synergistic function of DNA methyltransferases Dnmt3a and Dnmt3b in the Méthylation of Oct4 and Nanog. Mol Cell Biol 2007; 27:8748-8759.
71. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447:433-440.
72. Dammann R, Schagdarsurengin U, Seidel C et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005; 20:645-663.
73. Neuhausen A, Florl AR, Grimm MO et al DNA méthylation alterations in urothelial carcinoma. Cancer Biol Hier 2006; 8:993-1001.
74. Shen L, Kondo Y, Rosner GL et al MGMT promoter méthylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97:1330-1338.
75. Siegmund KD, Connor CM, Campan M et al. DNA méthylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS ONE 2007; 2:e895.
76. Issa JP. Aging, DNA méthylation and cancer. Crit Rev Oncol Hematol 1999; 32:31-43.
77. Fridman AL, Tang L, Kulacva OI et al Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle and cytoskeleton. J Gerontol A Biol Sci Med Sci 2006; 61:879-889.
78. Schulz WA, Alcxa A, Jung V et al. Factor interaction analysis for chromosome 8 and DNA méthylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 2007; 6:14.
79. Liu L, Zhang J, Bates S et al A méthylation profile of in vitro immortalized human cell lines. Int J Oneok2005; 26:275-285.
80. Suzuki MM, Bird A. DNA méthylation landscapes: provocative insights from epigenomics. Nat Rev Genet2008; 9:465-476.
81. Ptak C, Pctronis A. Epigenetics and complex disease: from etiology to new therapeutics. Annu Rev Pharmacol Toxicol 2008; 48:257-276.
82. Strathdee G, Brown R. Aberrant DNA méthylation in cancer: potential clinical interventions. Expert Rev Mol Med 2002; 4:10-17.